Browsing by author "Somaiah, Navita"
Now showing items 1-20 of 37
-
5-fraction radiotherapy for breast cancer: FAST Forward to implementation.
Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; et al. -
5-fraction radiotherapy for breast cancer: FAST Forward to implementation.
Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; et al. (Elsevier, 2023-05-19) -
Acceleration-Based Kalman Tracking for Super-Resolution Ultrasound Imaging In Vivo
Huang, B; Yan, J; Morris, M; Sinnett, V; Somaiah, N; et al. (IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC, 2023-12-01) -
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Brunt, AM; Wheatley, D; Yarnold, J; Somaiah, N; Kelly, S; et al. (ELSEVIER IRELAND LTD, 2016-07-15)BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin ... -
An ionising radiation-induced specific transcriptional signature of inflammation-associated genes in whole blood from radiotherapy patients: a pilot study.
Cruz-Garcia, L; Badie, C; Anbalagan, S; Moquet, J; Gothard, L; et al. (BMC, 2021-05-03)BACKGROUND: This communication reports the identification of a new panel of transcriptional changes in inflammation-associated genes observed in response to ionising radiation received by radiotherapy patients. METHODS: ... -
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
Sobhani, F; Robinson, R; Hamidinekoo, A; Roxanis, I; Somaiah, N; et al. (ELSEVIER, 2021-02-06)The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ... -
Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.
Somaiah, N; Chua, MLK; Bourne, S; Daley, F; A' Hern, R; et al. (ELSEVIER IRELAND LTD, 2016-05-15)AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT). PATIENTS AND METHODS: Patients given whole ... -
Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
Nuta, O; Somaiah, N; Boyle, S; Chua, MLK; Gothard, L; et al. (ELSEVIER IRELAND LTD, 2016-05-01)Late normal tissue toxicity varies widely between patients and limits breast radiotherapy dose. Here we aimed to determine its relationship to DNA damage responses of fibroblast cultures from individual patients. Thirty-five ... -
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
Okines, A; Irfan, T; Khabra, K; Smith, I; O'Brien, M; et al. (WILEY, 2018-05-01)Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients ... -
Dicentric Dose Estimates for Patients Undergoing Radiotherapy in the RTGene Study to Assess Blood Dosimetric Models and the New Bayesian Method for Gradient Exposure.
Moquet, J; Higueras, M; Donovan, E; Boyle, S; Barnard, S; et al. (RADIATION RESEARCH SOC, 2018-09-20)The RTGene study was focused on the development and validation of new transcriptional biomarkers for prediction of individual radiotherapy patient responses to ionizing radiation. In parallel, for validation purposes, this ... -
Does breast composition influence late adverse effects in breast radiotherapy?
Juneja, P; Bonora, M; Haviland, JS; Harris, E; Evans, P; et al. (CHURCHILL LIVINGSTONE, 2016-04-01)BACKGROUND: Large breast size is associated with increased risk of late adverse effects after surgery and radiotherapy for early breast cancer. It is hypothesised that effects of radiotherapy on adipose tissue are responsible ... -
FDXR is a biomarker of radiation exposure in vivo.
O'Brien, G; Cruz-Garcia, L; Majewski, M; Grepl, J; Abend, M; et al. (NATURE PORTFOLIO, 2018-01-15)Previous investigations in gene expression changes in blood after radiation exposure have highlighted its potential to provide biomarkers of exposure. Here, FDXR transcriptional changes in blood were investigated in humans ... -
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; et al. (SPRINGER, 2018-08-01)BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ... -
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
Brunt, AM; Haviland, JS; Kirby, AM; Somaiah, N; Wheatley, DA; et al. (ELSEVIER SCIENCE LONDON, 2021-06-10)INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the ... -
From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy.
Yarnold, JR; Brunt, AM; Chatterjee, S; Somaiah, N; Kirby, AM (ELSEVIER SCIENCE LONDON, 2022-05-01)There is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of hypofractionation in breast cancer derived from a series of clinical trials ... -
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.
Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-24)Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ... -
How Low Can You Go? The Radiobiology of Hypofractionation.
Brand, DH; Kirby, AM; Yarnold, JR; Somaiah, N (ELSEVIER SCIENCE LONDON, 2022-05-01)Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) ... -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Haviland, J; Sydenham, M; Hopwood, P; Kirby, A; Somaiah, N; et al. -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; et al. (ELSEVIER SCIENCE INC, 2020-05-23)BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ... -
Individualising radiation therapy decisions in breast cancer patients based on tumour infiltrating lymphocytes and genomic biomarkers.
Machiels, M; Oulkadi, R; Tramm, T; Stecklein, SR; Somaiah, N; et al. (CHURCHILL LIVINGSTONE, 2023-10-01)Radiation therapy (RT) has long been fundamental for the curative treatment of breast cancer. While substantial progress has been made in the anatomical and technological precision of RT delivery, and some approaches to ...